Priority Review
An FDA designation that fast-tracks the evaluation of a drug application, aiming for a decision within six months instead of the standard ten.
Priority Review is a special designation granted by the U.S. Food and Drug Administration (FDA) to drug applications that, if approved, would offer significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious medical condition. For biotechnology and pharmaceutical investors, a Priority Review designation is a major milestone. It shortens the FDA's goal for reviewing a Biologics License Application (BLA) or New Drug Application (NDA) from the standard ten months to six months. This accelerated timeline reduces the time-to-market, lowers development costs, and extends the commercial runway of the drug under patent protection. When evaluating a biotech stock, investors view Priority Review as both a validation of the drug's therapeutic potential and a catalyst that pulls forward the critical regulatory decision date (PDUFA date). This reduces the duration of pre-approval binary risk, though it does not guarantee final regulatory approval.
Biotech Company A receives a Priority Review designation for its new oncology drug. Instead of waiting the standard 10 months for an FDA decision, the review timeline is shortened to 6 months, pulling the expected PDUFA decision date forward by 4 months and accelerating potential commercialization.